<DOC>
	<DOCNO>NCT02850718</DOCNO>
	<brief_summary>A comparative bioequivalence study 48 healthy male volunteer oral Viagra test sublingual sildenafil wafer .</brief_summary>
	<brief_title>A Pivotal Study Bioequivalence Oral Viagra® Test Sublingual Sildenafil Wafer</brief_title>
	<detailed_description>Healthy volunteer complete two inpatient study period receive either sublingual wafer sildenafil oral sildenafil . Plasma sample adverse event collect .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Voluntarily provide sign , write , date informed consent prior studyspecific procedure . 2 . Healthy male volunteer age 1850 year inclusive . 3 . In good general health without clinically significant haematological , cardiac , respiratory , renal , endocrine , gastrointestinal , psychiatric , hepatic , malignant disease , determine Principal Investigator . 4 . Sufficient access venous cannulation withdraw blood per study design . 5 . Body mass index ( BMI ) ≥19 ≤ 30kg/m2 ( inclusive ) . 6 . Participant deem able read understand English order communicate research staff complete protocol require questionnaire form . 7 . Able refrain smoke research unit . 1 . Past history hypersensitivity sildenafil , excipients , severe allergic anaphylactic reaction drug . 2 . A medical condition , opinion Investigator , may adversely impact participant 's ability complete study , include limited : 1 . History priapism ; 2 . History easy fainting symptomatic postural hypotension ; 3 . Standing supine systolic blood pressure &lt; 90mmHg diastolic blood pressure &lt; 50mm Hg postural drop &gt; 30mm Hg ; 4 . History myocardial infarction clinically significant cardiac disease include cardiac arrhythmia ; 5 . History retinitis pigmentosa optic neuropathy risk factor nonarteritic anterior ischaemic optic neuropathy ( NAION ) ; 6 . History evidence hypertension define three BP reading ( rest ) within 15 minute systolic blood pressure ≥140 mm Hg diastolic blood pressure ≥90 mmHg . Note : serial blood pressure reading require initial reading elevate ; 7 . Anaemia ( haemoglobin &lt; low limit normal sex ) . 3 . Clinically significant 12lead ECG abnormality screen visit determine Investigator . 4 . Concomitant consumption medication regularly , exception vitamin mineral . 5 . Consumption drug either enzymeinducing property , rifampicin St John 's Wort , within 3 week prior initial dose study drug throughout treatment phase CYP3A4 inhibitor , erythromycin clarithromycin , within 5 halflives prior initial dose study drug throughout treatment phase . 6 . Previous know suspected drug abuse ( include analgesic drug tranquilizer ) dependence , define DSMIV , history alcohol abuse excessive intake alcohol , define regular weekly intake &gt; 15 unit men &gt; 10 unit woman ( 1 unit= 25ml spirits,125ml wine , 250ml beer lager ) . 7 . Positive result urine drug screen indicative illicit drug abuse inconsistent medication history , alcohol breath test indicative alcohol abuse . 8 . History hepatitis B C , form noninfectious liver disease . 9 . Clinically significant abnormality clinical chemistry , haematology , urinalysis , serology result screen , opinion Investigator , put volunteer risk study participation . 10 . Clinically significant plasma AST , ALT ALP test ( define ≥1.5 time upper limit normal ) . 11 . Positive serology human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection screen . 12 . Prevalent abnormality oral cavity may alter sublingual drug absorption ( e.g . recurrent oral ulceration , lichen planus , xerostomia ) . 13 . Any condition , opinion Investigator , make volunteer unsuitable study . 14 . Unwillingness inability comply requirement protocol , include presence condition ( physical , mental , social ) likely affect participant 's ability return follow visit schedule . 15 . Member relative study staff Sponsor directly involve study . 16 . Previous participation study . 17 . Has receive another investigational agent new chemical entity ( define compound approve marketing ) within 30 day prior Screening visit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>